RNS
REACH
TheraCryf
plc
("TheraCryf", the "Company" or the "Group")
European Patent Office
decision to award patent for Ox-1 antagonist
Alderley Park, UK - 27 November 2024: TheraCryf
plc (AIM: TCF), the clinical stage drug
development company focussing on oncology and
neuropsychiatry has received the decision
from the European Patent Office to award a Composition of Matter
patent for its Orexin 1 (Ox-1) receptor
antagonist in Europe, with a formal grant to be made on 18 December
2024.
TheraCryf's highly selective Ox-1 receptor
antagonist was acquired as part of its acquisition of Chronos
Therapeutics Ltd in April 2024. An imbalance in Orexin
production and stimulation of the Orexin 1 receptor in the brain
has been linked to anxiety, addiction and other mental health
conditions. An Orexin 1 receptor antagonist inhibits the effect of
Orexin on this receptor, potentially providing effective treatments
for these disorders. TheraCryf's Ox-1 is the most selective Orexin
1 receptor antagonist thus far discovered and is currently at
late pre-clinical stage.
This patent adds to TheraCryf's extensive
international IP portfolio covering its oncology and
neuropsychiatry products.
Dr Huw Jones,
TheraCryf's CEO, commented:
"Composition
of Matter patents such as this are the strongest form of
intellectual property available. This decision will give extensive
protection for our candidate Ox-1 receptor antagonist and
associated novel molecular structures in the broad group of
territories covered by the European Patent Office, complementing
the patents in this family already awarded in the USA and
Asia."
-Ends-
Enquiries
|
TheraCryf plc
Dr Huw Jones, CEO
Toni Hänninen, CFO
Dr Helen Kuhlman, CBO
|
+44 (0)1625 315
090
enquiries@theracryf.com
|
|
Cavendish Capital Markets (NOMAD and Broker)
Geoff Nash / Teddy Whiley / Rory Sale (Corporate
Finance)
Nigel Birks / Harriet Ward
(ECM)
|
+44 (0)20
7220 0500
|
|
Vigo Consulting
Rozi
Morris
|
+44 (0)20 7390 0231
theracryf@vigoconsulting.com
|
About TheraCryf plc
TheraCryf is the clinical stage drug
development company focussing on oncology and neuropsychiatry. The
Company has a broad clinical and preclinical pipeline in
indications including glioblastoma* neurodevelopmental disorders,
addiction, anxiety and narcolepsy [*orphan indication].
The Company's strategy is to
generate compelling data sets to preclinical and/or clinical proof
of concept and partner its clinical programmes with mid-size to
large pharma for larger trials and commercialisation. As well as a
number of industry partnerships with companies, including Stalicla
SA, in neurodevelopmental disorders. The Company has sourced
know how for programmes from companies such as Shire (now
Takeda).
TheraCryf has worked with and has
ongoing collaborations with major universities and hospitals such
as the University of Manchester, La Sapienza (Università di Roma),
the Erasmus Medical Centre, Rotterdam, Kings College London and the
University of Michigan.
The Company has its headquarters and
registered office at Alderley Park, Cheshire. It is quoted on AIM
in London and trades under the ticker symbol TCF.
For further information, please
visit: www.theracryf.com